Last month, Millennium CEO Deborah Dunsire stepped down and company veteran Anna Protopapas stepped in as president of the company, which will no longer operate as autonomously as it had before the reorganization. The reorganization will also come at the expense of an undisclosed number of jobs.
Last week, Endo Health Solutions said two of its top officers were leaving, no explanations offered. Today, we have a possible reason: the wholesale restructuring of the company.
Fresh from an FDA denial of its long-acting testosterone injection and other setbacks, Endo Health Solutions plans to ax 15% of its workforce in an effort to reduce expenses. The cutbacks come as the Malvern, PA-based company faces generic competition against two of its highest-selling painkillers, Opana ER and Lidoderm.
Impax Laboratories is cutting roughly 10% of its workforce, or 110 jobs, after problems at its manufacturing plant in California cost it FDA consideration of a drug application and then a partnership with GlaxoSmithKline.
Australia respiratory drugmaker Pharmaxis said it will cut 48 jobs in its manufacturing and clinical areas to save $12 million after the FDA asked for additional data on its Bronchitol treatment for cystic fibrosis.
The biotech says it will cut 48 jobs, or about a third of its workforce, as it gets ready to try to satisfy regulators with another study of the therapy, which is marketed in Europe.
The company is considering cutting back its field force of about 14,600 by as much as one-third, the sources said.
While many of the big-time medical device companies are forecasting sunny earnings for 2013, that hasn't slowed down the march to trim payroll, as companies from Accuray to Zimmer have announced thousands of layoffs since Jan. 1. Read more >>
GlaxoSmithKline is pretty proud of its rotacaps and its blow-fill-seal lines at its packaging plant in the Melbourne, Australia, suburb of Boronia. Its tablet line, not so much, and the drugmaker will eliminate that line and lay off about a third of the workforce at the facility.
Another Big Pharma CEO is having a pep talk with employees about manufacturing lapses and the need to reflect on quality.